The side effects of dopamine receptor agonist drugs in Chinese prolactinoma patients: a cross sectional study.

Abstract

BACKGROUND:

Recently, side effects from Dopamine Receptor Agonist Drugs (DAs) in treating pituitary prolactinoma have raised widespread concern. This study explores the incidence and influencing factors of DAs-related side effects in Chinese prolactinoma patients.

METHODS:

A cross-sectional study was conducted. 51 prolactinoma patients treated with DAs, 12 prolactinoma or pituitary microadenoma patients without DAs treatment, and 33 healthy controls were included. The Barratt impulsivity scale-11, Patient Health Questionnaire 9, and the ICD screening questionnaire were all used to evaluate the psychological and physical side effects of DAs. Clinical data of all subjects were collected from their electronic medical records.

RESULTS:

The incidence of ICDs in the treated group, the untreated group, and control group was 9.8% (5/51), 16.7% (2/12), and 9.1% (3/33), respectively. In the treated group in particular, there were 1 patient (2%, 1/51), 2 patients (3.9%, 2/51), and 2 patients (3.9%, 2/51) with positive screening for punding, compulsive shopping, and hypersexuality, respectively. In terms of depression, the incidence of "minimal", "mild" and "moderate" depression in the treated group was 62.8% (32/51), 25.5% (13/51), and 5.9% (3/51), respectively. The incidence of physical symptoms was 51.0% (26/51) in the treated group and gastrointestinal symptoms were the most common symptoms (33.3%, 17/51). In addition, we found that the various parameters of DAs treatment had no association with the occurrence of physical symptoms or ICDs (all P > 0.05).

CONCLUSIONS:

Chinese prolactinoma patients treated with DAs had a lower incidence of ICDs (9.8%), while gastrointestinal symptoms were common. In this way, more attention should be paid to side effects, especially physical symptoms, in Chinese prolactinoma patients with DAs therapy during follow-up regardless of dose.

• Authors: Xiaoan Ke, Linjie Wang, Meiping Chen, Shanshan Liu, Na Yu, Lian Duan, Fengying Gong, Huijuan Zhu
• Journal: BMC endocrine disorders (BMC Endocr Disord) Vol. 22 Issue 1 Pg. 97 (Apr 11 2022) ISSN: 1472-6823 [Electronic] England
• PMID: 35410236 (Publication Type: Journal Article)
• Copyright: © 2022. The Author(s).

Chemical References

• Dopamine Agonists

Topics

• China (epidemiology)
• Cross-Sectional Studies
• Disruptive, Impulse Control, and Conduct Disorders (chemically induced, drug therapy)
• Dopamine Agonists (adverse effects)
• Humans
• Pituitary Neoplasms (drug therapy, epidemiology)
• Prolactinoma (drug therapy, epidemiology)